Notice Number: NOT-HL-17-485
Key Dates
Release Date: February 1, 2017
Estimated Publication Date of Announcement: Spring 2017
First Estimated Application Due Date: Fall 2017
Earliest Estimated Award Date: Spring 2018
Earliest Estimated Start Date: Spring 2018
Issued by
National Heart, Lung, and Blood Institute (NHLBI)
Purpose
The National Heart, Lung, and Blood Institute (NHLBI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) which will establish a program to advance translational research in cancer related thrombosis.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations between oncologists and coagulation/vascular experts and appropriate projects.
This FOA will utilize the U01 activity code. Details of the planned FOA are provided below.
The intended FOA will 1) encourage studies in individual cancer types that expand mechanistic investigation into the intersection between cancer and thrombotic pathways; and 2) apply mechanistic insights towards the identification and development of markers of thrombotic risk or cancer progression and new strategies for preventing or treating the deleterious interplay between cancer, cancer therapy, and hemostasis/thrombosis.
A multi-PD/PI U01 cooperative agreement mechanism will support the collaborative efforts of oncologists and coagulation/vascular experts to identify, further develop, and implement advances in thrombosis and hemostasis research into practice for cancer patients. Applicants will be asked to focus their research project on thrombosis associated with one or more of the following cancers: brain, ovary, pancreas, colon, stomach, lung, liver, bladder, and kidney. This program is not intended to support interventional clinical trials in the area of cancer related thrombosis.
APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.
Inquiries
Please direct all inquiries to:
Andrei Kindzelski
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0050
Email: [email protected]